

Clinical trials of ertugliflozin

TrialResults-center www.trialresultscenter.org

1 diabetes type 2

Trial	Treatments	Patients	Trials design and methods
ertugliflozin vs placebo			
VERTIS CV <i>ongoing</i> [NCT01986881] n=8000 follow-up:	Ertugliflozin 15 mg and 5 mg versus placebo	participants with type 2 diabetes mellitus and established vascular disease	

More details and results :

- glucose lowering for cardiovascular prevention for diabetes type 2 in all type of patients at <http://www.trialresultscenter.org/go-Q576>
- glucose lowering for cardiovascular prevention for diabetes type 2 in meta-regression at <http://www.trialresultscenter.org/go-Q692>

References

VERTIS CV, :

ongoing trial NCT01986881